ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a leading player in the biopharmaceutical industry, is headquartered in Shanghai, China. Founded in 2015, the company has rapidly established itself as a pioneer in the development of innovative immuno-oncology therapies, focusing on harnessing the body’s immune system to combat cancer. With a robust portfolio of unique products and services, ImmuneOnco is dedicated to advancing cancer treatment through cutting-edge research and development. The company’s commitment to excellence has positioned it as a key contributor in the global biopharmaceutical landscape, particularly in the Asia-Pacific region. Notable achievements include significant partnerships and advancements in clinical trials, underscoring its role in transforming cancer care.
DitchCarbon Score
How does ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s score of 20 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s reported carbon emissions
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., headquartered in China, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. As there are no emissions data or reduction initiatives available, it is unclear how ImmuneOnco Biopharmaceuticals aligns with industry standards for climate action. The absence of emissions reporting may reflect a broader trend within the biopharmaceutical sector, where companies are increasingly being urged to disclose their environmental impact and set ambitious targets for emissions reduction. In summary, without available emissions data or climate commitments, ImmuneOnco Biopharmaceuticals has yet to demonstrate a proactive approach to managing its carbon footprint.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
